Navigation Links
Hormone Therapy Not Best for Older Prostate Cancer Patients
Date:9/23/2008

Study found giving it before radiation raised death risk 20% in this group

TUESDAY, Sept. 23 (HealthDay News) -- Older men with early-stage prostate cancer who are given hormone therapy before radiation seed implant therapy face a 20 percent greater risk of dying than those who get radiation treatment alone, new research suggests.

Focusing on men over the age of 70, the study summed up the risks of death from any cause linked to androgen-deprivation therapy. Such treatment is sometimes given before radiation treatment to lower male hormone levels, shrink the prostate, and retard cancer growth. Brachytherapy itself involves the insertion of small radioactive seeds into the prostate to destroy cancer cells.

"We know that hormone therapy has a lot of side effects," noted study author Dr. Amy M. Dosoretz, a radiation oncology resident with the Harvard Radiation Oncology Program in Boston. "Depression, fatigue and anemia, among others. Yet it can be worth it, because it has a significant benefit for many patients. But for some patients, the risks may outweigh the benefits. And here, we found that in this particular group of patients -- early-stage prostate cancer patients over 70 -- there was an increased risk for mortality."

Dosoretz and her colleagues were expected to present their findings Tuesday at the American Society for Therapeutic Radiology and Oncology annual meeting, in Boston.

The team's risk assessment is based on a mortality analysis involving more than 1,700 early-stage, localized prostate cancer patients. The men were between the ages of 70 and 91, and received either hormone and brachytherapy treatments or brachytherapy alone between 1991 and 2005.

For those who received hormone therapy, treatment lasted three and a half months on average.

The authors found that undergoing such hormonal intervention was associated with an increased risk of dying from all causes. Being older and having a more aggressive form of prostate cancer was similarly associated with an increased risk of dying from all causes.

"But we still don't know exactly why there's an increased risk for mortality for these patients," Dosoretz cautioned. "So, we need to look into this important issue further, with randomized trials that take in all the bias. Meanwhile, when deciding about hormone therapy treatment, it's important -- especially among elderly men who have early-stage prostate cancer -- to really weigh the benefits and risks."

Dr. Charles J. Ryan, a urologic cancer specialist and an assistant clinical professor of medicine in the division of hematology/oncology at the University of California, San Francisco, agreed.

"We have a pretty good sense that hormone therapy can increase the relative risk for cardiac risk, diabetes and some of the major problems that are likely to kill patients with prostate cancer," Ryan noted. "However, here, the researchers do not address prostate-cancer specific mortality but rather all-cause mortality. And it does a disservice to what hormone therapy can do well to ignore the fact that there have been several studies going back years that show that hormone therapy in addition to radiation improves survival for high-risk patients."

"So, basically, the decision with what to do with hormone therapy needs to be taken in the context of risk," Ryan said.

More information

For additional details on early-stage prostate cancer treatment, visit the National Cancer Institute.



SOURCES: Amy M. Dosoretz, M.D., radiation oncology resident, Harvard Radiation Oncology Program, Boston; Charles J. Ryan, M.D., assistant clinical professor, medicine, division of hematology/oncology, University of California, San Francisco; Sept. 23, 2008, presentation, American Society for Therapeutic Radiology and Oncology meeting, Boston


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Johns Hopkins researchers suppress hunger hormone
2. Acupuncture may hold promise for women with hormone disorder
3. UCLA and biotech company develop first blood test to measure key hormone that regulates iron
4. Monitoring Hormone May Improve Kidney Failure Outcomes
5. Thyroid Hormone May Boost Womens Alzheimers Risk
6. A hormone that enhances ones memory of happy faces
7. Menopause: Hot Flashes Can Be Reduced 90% without Hormones
8. Suckling Infant Triggers Trust Hormone in Moms
9. Hormone Replacement May Raise Womens Gallbladder Risk
10. Hormone Therapy Shows Little Benefit Against Prostate Cancer
11. Breakthrough "Neuro Nutrition" Targets the Brain and Vagus Nerve To Boost the Body's Immune, Hormone and Neurological Systems
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hormone Therapy Not Best for Older Prostate Cancer Patients
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 West Pharmaceutical Services, Inc. ... injectable drug administration, today announced that it will release ... Thursday, October 26, 2017, and will follow with a ... at 9:00 a.m. Eastern Time. To participate on the ... conference ID is 94093362. ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017  According to the Centers for ... the end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the ... as mandated by certain health insurance regulations. ... The best time to get a flu shot is by the ...
Breaking Medicine Technology: